Boston Scientific announces results for third quarter 2026
PR Newswire•28/10/2026•06:30 ET
0
Key Highlights
- ➤Q3 net sales $5.138 billion, up 1.5% reported, operational and organic
- ➤GAAP EPS $0.40 versus $0.51; adjusted EPS $0.73 versus $0.75
- ➤Full-year adjusted EPS guidance now stands at $3.16 to $3.18
- ➤Q4 sales expected to decline approximately 1.0% to 3.0% year over year
- ➤Boston Scientific entered an AI-powered PCI planning collaboration with Heartflow (HTFL)
Expert Statements
Mike Mahoney, Chairman and chief executive officer of Boston Scientific
“This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients. As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.”
Boston Scientific announces results for third quarter 2026 PR Newswire
MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational(1) and organic(2) basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $582 million or $0.40 per share (EPS), compared to $755 million or $0.51 per share a year ago, and achieved adjusted(3) EPS of $0.73 for the period, compared to $0.75 a year ago.
Get started
Create a free account to read the full story.